Gangguan Cemas Menyeluruh

01Pathophysiology

Generalized Anxiety Disorder arises from a complex interplay of neurobiological and psychological dysfunction. At the core is a dysregulation of the brain's fear and worry circuits, primarily involving the amygdala, prefrontal cortex, and their interconnections.

The amygdala, responsible for threat detection, is tonically hyperactive in GAD patients. Under normal conditions, the prefrontal cortex exerts top-down inhibitory control over the amygdala, allowing a person to appraise threats rationally and suppress unnecessary alarm responses. In GAD, this prefrontal-amygdala regulatory loop is impaired, meaning the brain cannot effectively "turn off" the worry signal. This is why patients describe their anxiety as persistent, pervasive, and difficult to control; it is not triggered by a single object or situation (as in phobias) but instead floats freely across multiple domains of life.

At the neurotransmitter level, GABA (gamma-aminobutyric acid) is the principal inhibitory neurotransmitter in the central nervous system. In GAD, there is reduced GABAergic tone, leading to a state of chronic neural excitability. This explains why benzodiazepines, which enhance GABA-A receptor activity, provide rapid symptomatic relief. Additionally, serotonin (5-HT) pathways originating from the dorsal raphe nuclei are dysregulated, contributing to sustained anxious mood and ruminative worry. This is the rationale for using SSRIs and SNRIs as first-line pharmacotherapy.

The three symptom clusters described in PPDGJ-III map directly onto this pathophysiology:

Anxiety and apprehension (worry about bad outcomes, feeling on edge, poor concentration) reflect the cognitive dimension of a chronically activated threat-detection system. The prefrontal cortex is "hijacked" by persistent worry loops, reducing its capacity for other cognitive tasks such as attention and working memory.

Motor tension (restlessness, headache, tremor, inability to relax) results from sustained activation of the corticospinal motor pathways. The brain, perceiving constant threat, maintains the musculature in a state of preparedness for fight-or-flight. Over time, this chronic muscle contraction produces tension headaches, myalgias, and subjective restlessness.

Autonomic overactivity (palpitations, sweating, lightheadedness, dry mouth, epigastric distress, shortness of breath) reflects tonic activation of the sympathetic nervous system via the hypothalamic-pituitary-adrenal (HPA) axis and sympatho-adrenomedullary system. Elevated cortisol and catecholamines drive the cardiovascular, respiratory, and gastrointestinal symptoms that patients frequently report. Notably, many patients present to primary care or emergency departments with these somatic complaints rather than explicitly stating they feel anxious, which is a classic exam trap.

In children, the pathophysiology manifests differently. The immature prefrontal cortex has even less inhibitory control over the amygdala, so children express anxiety through excessive reassurance-seeking behavior and recurrent somatic complaints (stomachaches, headaches) rather than through verbalized worry.

02Classification and Clinical Manifestation

PPDGJ-III does not subclassify GAD into formal subtypes, but the clinical manifestations are organized into three symptom domains. The following table summarizes each domain with its characteristic features:

Duration and Character of Symptoms

03Diagnostic Workup

GAD is a clinical diagnosis. There is no laboratory test, imaging study, or biomarker that confirms it. The diagnosis is made when a patient meets PPDGJ-III criteria: anxiety as the primary symptom, present almost daily for weeks to months, free-floating in nature, with symptoms spanning the three domains of apprehension, motor tension, and autonomic overactivity.

The best initial step in any exam vignette presenting with chronic anxiety symptoms is to take a thorough psychiatric history and apply the PPDGJ-III diagnostic criteria. A structured rating scale such as the HAM-A can be used to quantify severity, but it is not required for diagnosis.

The most important diagnostic task is not to confirm GAD but to exclude organic and psychiatric mimics. Hyperthyroidism is the classic medical condition that mimics GAD almost perfectly (anxiety, tremor, palpitations, sweating, weight loss), so TSH should be checked in every patient. Pheochromocytoma, though rare, can present with episodic anxiety and autonomic symptoms; urine metanephrines are ordered if clinical suspicion is high. Stimulant use (amphetamines, cocaine, excessive caffeine) should be excluded through history and, if necessary, urine drug screen.

On the psychiatric side, the clinician must ensure that the symptoms do not better fit panic disorder (episodic, paroxysmal attacks with intense fear peaking within minutes), phobic anxiety disorder (anxiety bound to a particular object or situation), obsessive-compulsive disorder (anxiety driven by intrusive thoughts and compulsive rituals), or a depressive episode (where low mood, anhedonia, and psychomotor changes dominate). Per PPDGJ-III, brief depressive symptoms lasting a few days do not exclude GAD, as long as they do not meet the full diagnostic threshold for any of these alternative diagnoses.

04Management and Treatment

Acute Phase. When a patient presents with functionally impairing anxiety, the first decision is whether pharmacotherapy, psychotherapy, or both are indicated. For mild GAD, CBT alone may suffice. For moderate to severe GAD, pharmacotherapy plus CBT is the recommended approach.

The first-line drug is an SSRI. Sertraline is commonly chosen at a starting dose of 50 mg once daily, titrated as needed to a maximum of 200 mg/day. Escitalopram can be started at 10 mg daily. The critical teaching point is that SSRIs take 2 to 4 weeks to reach therapeutic effect, and patients must be counseled about this delay to prevent premature discontinuation.

During this lag period, benzodiazepines may be prescribed as a bridge for patients with severe or debilitating symptoms. Alprazolam 0.25 to 0.5 mg three times daily or lorazepam 0.5 to 1 mg two to three times daily provides rapid relief. However, benzodiazepines carry risks of tolerance, dependence, and withdrawal, so they should be tapered and discontinued within 2 to 4 weeks once the SSRI takes effect. This "bridge then taper" concept is a favorite exam target.

Buspirone is an alternative anxiolytic that acts as a partial agonist at the serotonin 5-HT1A receptor. It has no sedative properties, no abuse potential, and no cross-tolerance with benzodiazepines. It is started at 5 mg three times daily and titrated to 20-30 mg/day. Like SSRIs, it requires 2 to 4 weeks to become effective, so it cannot be used for acute relief.

Long-Term Maintenance. GAD is a chronic, relapsing condition. Pharmacotherapy should be continued for at least 12 months after symptom remission before considering a gradual taper. Abrupt discontinuation of SSRIs or SNRIs can cause discontinuation syndrome (dizziness, nausea, irritability, "brain zaps"), so medications should always be tapered slowly over weeks.

Contraindications and Cautions. Benzodiazepines should be avoided in patients with a history of substance use disorder, elderly patients (fall risk, cognitive impairment), and pregnant women (teratogenic risk, neonatal withdrawal). Venlafaxine can raise blood pressure at higher doses and requires monitoring. SSRIs carry a risk of serotonin syndrome if combined with MAOIs or other serotonergic agents; a washout period of at least 2 weeks is required when switching between these classes.

The "Next Best Step" Logic. If an exam vignette shows a patient already on an adequate SSRI dose for 6-8 weeks with no response, the next best step is to switch to a different SSRI or to an SNRI, not to add a benzodiazepine indefinitely. If partial response is achieved, augmentation with buspirone is a reasonable option.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on GAD questions is by confusing it with panic disorder. Both conditions live under the umbrella of anxiety disorders and share overlapping autonomic symptoms, but the distinction is straightforward once you internalize one rule: GAD is chronic and continuous, while panic disorder is episodic and paroxysmal. If the vignette describes a patient who has been feeling "worried all the time for months" with no discrete attacks, the answer is GAD. If the vignette describes sudden, intense episodes of terror peaking within 10 minutes, the answer is panic disorder. Test-writers love to blur this line by including autonomic symptoms in both, so anchor your decision on the temporal pattern, not the symptom list.

A second trap involves the somatic presentation. Many GAD vignettes deliberately hide the psychiatric diagnosis behind a wall of physical complaints: chronic headaches, palpitations, GI upset, dizziness. The student who does not think beyond the organ system will chase cardiac workups or GI evaluations and miss the underlying anxiety disorder. The giveaway is always a negative medical workup in a patient with chronic, multi-system somatic complaints. When labs and imaging are all normal and the patient has been "doctor shopping," think GAD.

Third, pay attention to the PPDGJ-III rule about coexisting depressive symptoms. A vignette may include a few days of low mood to tempt you into choosing depression. Per PPDGJ-III, transient depressive features do not cancel the GAD diagnosis unless they independently meet the full criteria for a depressive episode. If the stem says "the patient also felt sad for the past three days" but otherwise describes months of free-floating anxiety, the answer remains GAD.

Finally, in management questions, the classic trap is selecting a benzodiazepine as long-term monotherapy. Benzodiazepines are effective acutely but are never the answer for long-term management of GAD due to dependence risk. The correct long-term answer is always an SSRI or SNRI, with or without CBT. If the question asks for the "next best step" after initial stabilization, it is to start an SSRI and plan to taper the benzodiazepine.

The core competency being tested in GAD questions is the ability to recognize a chronic, free-floating anxiety pattern in a patient who may present with somatic complaints, distinguish it from episodic or situationally bound anxiety disorders, and select appropriate stepwise management that prioritizes long-term safety over short-term relief.